Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 9506066
    Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 29, 2016
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Joyce Eskdale, Rachael Siegel
  • Patent number: 9499624
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Marlene Thomas, Carola Ries, Stefan Seeber
  • Patent number: 9498543
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • Patent number: 9499625
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: November 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • Patent number: 9499612
    Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: November 22, 2016
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Ian Richard Catchpole, Zoe Hughes-Thomas, Alan Peter Lewis, Michael Steward
  • Patent number: 9474783
    Abstract: This invention concerns a HIP/PAP protein or derivative thereof, for its use in treating or managing cancer and preferentially solid tumors.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: October 25, 2016
    Assignees: ALFACT INNOVATION, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS SUD
    Inventors: Jamila Faivre, Eric Vibert, Marion Darnaud, Laure Jamot, Christian Brechot, Paul Amouyal, Gilles Amouyal
  • Patent number: 9428581
    Abstract: Provided is an antibody effective for treatment and/or prevention of gallbladder cancer. A pharmaceutical composition for treatment and/or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: August 30, 2016
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takanori Saito, Fumiyoshi Okano, Takayoshi Ido
  • Patent number: 9416193
    Abstract: Provided is an antibody effective for treatment and/or prevention of liver cancer. A pharmaceutical composition for treatment and/or prevention of liver cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: August 16, 2016
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takanori Saito, Fumiyoshi Okano, Takayoshi Ido, Yoshitaka Minamida
  • Patent number: 9416191
    Abstract: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: August 16, 2016
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
  • Patent number: 9409987
    Abstract: This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains of LY6G6F, VSIG10, TMEM25 and LSR and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders. This invention further relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LY6G6F, VSIG10, TMEM25 or LSR molecules, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: August 9, 2016
    Assignee: COMPUGEN LTD
    Inventors: Amir Toporik, Amit Novik, Ronen Shemesh
  • Patent number: 9400274
    Abstract: In general, the present invention relates to identification of lipidome biomarkers for cancer analysis and it provides prognostic and predictive methods and kits for cancer diagnosis and subtyping and for diagnosing and/or predicting the evolution of a tumor and its response to lipid metabolism-targeted or other types of therapy in a subject, by making use of phospholipid (PL) profiling, wherein changes in the combined acyl chain length of intact body fluid-derived or tumor-derived phospholipid species is indicative of an elongation phenotype.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: July 26, 2016
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Johannes Victor Maria Swinnen, Jelle Machiels, Eyra Marie-Jeanne Edel Leopold Marien, Muralidhara Rao Bagadi
  • Patent number: 9382306
    Abstract: The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: July 5, 2016
    Assignees: IPSEN PHARMA S.A.S., COMMISSARIAT A L'ENERGIE ATOMIQUE (CEA), LE CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Marie-Thérèse Paternostre, Jean-Christophe Cintrat, Céline Valery, Stéphane Roux, Bernard Rousseau, Maarten Ijsselstijn, Roland Cherif-Cheikh, Franck Artzner
  • Patent number: 9340618
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 17, 2016
    Assignee: CSL LIMITED
    Inventors: Kirsten Edwards, Matthew Hardy, Veronika Rayzman, Michael Wilson
  • Patent number: 9340613
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 17, 2016
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 9333257
    Abstract: The use of an FGFR1 antibody in the treatment of cancer is disclosed, wherein the FGFR1 antibody binds FGFR1 at an epitope that is positioned in the FGFR1 primary amino acid sequence no more than 50 contiguous amino acids away from the C- or N-terminal of the FGFR1 heparin binding domain.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: May 10, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon Cool, Victor Nurcombe, Ling Ling
  • Patent number: 9336349
    Abstract: An object of the present invention is to provide a simple and useful method for producing an RNA-containing probe for detecting a target nucleotide, a simple and useful method, device, and system for processing nucleotide sequence information, and a simple and useful method for detecting a target nucleotide. The present invention provides a method for processing nucleotide sequence information, the method comprising the step of generating partial nucleotide sequences which has 7 to 14 nucleotides and a Tm value of 25 to 40° C. and in which a target nucleotide or a nucleotide adjacent to the target nucleotide is located at a position between 3 and 5 nucleotides from the 3? or 5? end. The method according to the present invention is useful for simply and efficiently producing an RNA-containing probe for detecting a target nucleic acid, without the basis of researchers' experiences or guess, and are extremely useful not only in the field of genetic engineering, but also in the field of medical research.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: May 10, 2016
    Assignee: Takara Bio Inc.
    Inventors: Junko Yamamoto, Tomoo Inden, Toshiharu Ohba, Tooru Suzuki, Hiroyuki Mukai, Kiyozo Asada
  • Patent number: 9321838
    Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumor cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: April 26, 2016
    Assignee: Fusion Antibodies Limited
    Inventors: Shane Olwill, Christopher Scott, Julie Gormley, Jaquin Thomas, Roberta Burden, Darragh McMeel, James Johnston
  • Patent number: 9310353
    Abstract: A method to detect bioavailable metal ions from an oral care composition and a method to select for compounds that inhibit the uptake of metal ions into cells.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: April 12, 2016
    Assignee: THE PROCTER & GAMBLE COMPANY
    Inventors: John Christian Haught, Koti Tatachar Sreekrishna, Yakang Lin
  • Patent number: 9304127
    Abstract: Subject matter of the present invention is an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold wherein said antibody or said fragment or scaffold is a non-neutralizing antibody, antibody fragment or non-Ig scaffold, respectively. Subject matter of the present invention is also in anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in a treatment of a chronic or acute disease wherein said antibody or fragment or scaffold is an ADM stabilizing antibody or an adrenomedullin stabilizing antibody fragment or an ADM stabilizing non-Ig scaffold that enhances the t½ half retention time of adrenomedullin in serum, blood, plasma at least 10%, preferably at least, 50%, more preferably >50%, most preferably 100%, and/or wherein said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold blocks the bioactivity of ADM to not more than 80%, or not more than 50%.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: April 5, 2016
    Assignee: ADRENOMED AG
    Inventor: Andreas Bergmann
  • Patent number: 9273149
    Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: March 1, 2016
    Assignees: Veri-Q, Inc., North Carolina State University
    Inventors: Paul F. Agris, Christopher D. J. Pearce, Lloyd G. Mitchell
  • Patent number: 9266958
    Abstract: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: February 23, 2016
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
  • Patent number: 9260498
    Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: February 16, 2016
    Assignee: LEUKOLECT AS
    Inventors: Bernt Th. Walther, Mirushe Miftari
  • Patent number: 9248187
    Abstract: The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: February 2, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Lars Anders Bylock
  • Patent number: 9217745
    Abstract: A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: December 22, 2015
    Assignee: University of Rochester
    Inventors: Benjamin L. Miller, Tim R. Mosmann, David Topham, Charles R. Mace
  • Patent number: 9200071
    Abstract: The present invention relates to methods of treating cancer in general, and leukemia in particular, using Notch1 and Notch3 antagonists singly or in combination. Compositions and methods for the treatment and diagnosis of Notch-associated cancers are also provided.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: December 1, 2015
    Assignee: Genentech, Inc.
    Inventor: Christian W. Siebel
  • Patent number: 9201044
    Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 1, 2015
    Assignee: Integrated Diagnostics, Inc.
    Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
  • Patent number: 9186414
    Abstract: A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: November 17, 2015
    Assignee: UCL Business PLC
    Inventors: Peng T. Khaw, Stephen Brocchini, Ashkan Khalili
  • Patent number: 9187562
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 17, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9181305
    Abstract: The present invention relates to exendin-4 peptide analogs and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: November 10, 2015
    Assignee: SANOFI
    Inventors: Torsten Haack, Andreas Evers, Michael Wagner, Bernd Henkel, Siegfried Stengelin
  • Patent number: 9180139
    Abstract: The present disclosure is directed to a regulator, a pharmaceutical composition encompassing the regulator and the application thereof. The regulator modulates the expression integrins and/or EMP2, and is employed for treating integrins-associated and/or EMP2-associated diseases.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: November 10, 2015
    Assignee: National Cheng Kung University
    Inventors: Nan-Haw Chow, Hsiao-Sheng Liu, Yi-Wen Wang, Wen-Tsan Chang
  • Patent number: 9181333
    Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: November 10, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Christopher J. Bond
  • Patent number: 9163062
    Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: October 20, 2015
    Assignee: Aracion Biotech S.L.
    Inventor: J. Manuel Sarasa Barrio
  • Patent number: 9132179
    Abstract: Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneuomococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of either neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid. Optionally, the composition can comprise any combination of a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these. Optionally the agents are detoxified. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: September 15, 2015
    Assignee: The UAB Research Foundation
    Inventors: Frederik W. Van Ginkel, David E. Briles, James M. Watt
  • Patent number: 9120862
    Abstract: The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: September 1, 2015
    Assignees: ABBOTT LABORATORIES, ABBOTT JAPAN
    Inventors: Toru Yoshimura, Barry Lee Dowell, Gangamani S. Beligere, Eisaku Yoshida
  • Patent number: 9109025
    Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: August 18, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
  • Patent number: 9044460
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: June 2, 2015
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne King, Neeraj Kohli, Eric Krauland, Ulrik Nielsen
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150147333
    Abstract: Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 28, 2015
    Applicant: GENENTECH, INC.
    Inventors: Elaine Storm, Frederic J. de Sauvage, Jeremy M. Murray, Cameron L. Noland, Yan Wu, Christine Tan, Jo-Anne Hongo, Yongmei Chen
  • Publication number: 20150147331
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 28, 2015
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Publication number: 20150147329
    Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
    Type: Application
    Filed: July 25, 2014
    Publication date: May 28, 2015
    Inventors: Rahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
  • Publication number: 20150147334
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Publication number: 20150147321
    Abstract: A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.
    Type: Application
    Filed: February 4, 2015
    Publication date: May 28, 2015
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Toshihiko ISHII, Miyoko ASANO
  • Publication number: 20150147330
    Abstract: Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Mitchell Ho, Yen T. Phung, Wei Gao, Yifan Zhang
  • Patent number: 9040049
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 26, 2015
    Assignee: Vasgen Limited
    Inventors: Salman Rahman, Yatin Patel, Holger Gerhardt, Andrea Emma Lundkvist
  • Publication number: 20150140002
    Abstract: The present invention provides methods for treating hyperlipidemia in patients who are not on statin therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 21, 2015
    Inventors: Marie Baccara-Dinet, Laurence Bessac, Umesh Chaudhari, Corinne Hanotin, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
  • Publication number: 20150140003
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Publication number: 20150139999
    Abstract: Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 21, 2015
    Inventors: Sergei V. Kotenko, Geoffrey L. Smith
  • Publication number: 20150139990
    Abstract: The invention provides a method for the prophylaxis, improvement, or treatment of inflammatory bowel disease, multiple sclerosis, and psoriasis by administering to a subject an effective amount of an isolated anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of amino acid numbers 80 to 175 of SEQ ID NO:22.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventors: Takamasa WATANABE, Tadahiko YOSHIMA, Mikael MATTSSON, Anna SARNEFALT, Takuya HASEZAKI
  • Publication number: 20150139986
    Abstract: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and downmodulating immune responses in vitro, e.g., downmodulating alloimmune responses; the production of inflammatory cytokines by dendritic cells, e.g., monocyte-derived dendritic cells (MDDC); the upregulation of costimulatory molecules by DC, e.g., MDDC; and/or calcium flux in monocytes. In addition, the binding molecules upregulate the expression of inhibitory receptors on dendritic cells, e.g., immature dendritic cells. Surprisingly, these same binding molecules which downmodulate immune responses in vitro, are immunostimulatory in vivo. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: May 21, 2015
    Inventors: Paul Ponath, Patricia Rao, Michael Rosenzweig, Lesley Mary Smith, Jose F. Ponte
  • Publication number: 20150140000
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot